Shaghayegh Khanmohammadi , Mahdi Masrour , Parisa Fallahtafti , Amirhossein Habibzadeh , Art Schuermans , Mohammad Shafi Kuchay
{"title":"The relationship between nonalcoholic fatty liver disease and frailty: A systematic review and meta-analysis","authors":"Shaghayegh Khanmohammadi , Mahdi Masrour , Parisa Fallahtafti , Amirhossein Habibzadeh , Art Schuermans , Mohammad Shafi Kuchay","doi":"10.1016/j.dsx.2025.103187","DOIUrl":"10.1016/j.dsx.2025.103187","url":null,"abstract":"<div><h3>Background and aim</h3><div>Frailty is frequently observed in end-stage liver disease of various etiologies, but its role in nonalcoholic fatty liver disease (NAFLD) remains incompletely understood. We aimed to conduct a systematic review and meta-analysis to assess the association and prevalence of frailty in NAFLD.</div></div><div><h3>Methods</h3><div>A systematic review of PubMed/MEDLINE, EMBASE, Web of Science, and Scopus was performed. The random-effects model was used to estimate the pooled prevalence of frailty. Meta-analyzed odds ratios (OR) were calculated to examine the association between frailty and NAFLD.</div></div><div><h3>Results</h3><div>Among the initial 430 articles identified, 18 studies were included. Three studies involving 3673 participants had a pooled OR of 2.03 (95% CI: 1.51–2.72; I^2 = 1.1%; <em>p</em> < 0.0001) for the association between frailty and NAFLD. The pooled prevalence of frailty in individuals with NAFLD was 23% (95% CI: 13%–38%; I^2 = 93.5%) using the liver frailty index (LFI) and 8% (95% CI: 3%–21%; I^2 = 98.1%) using the Fried frailty index (FFI). NAFLD patients’ mean grip strength and balance time were 26.4 kg (95% CI: 23.0–29.8) and 23s (95% CI: 10–35), respectively. Among studies that also included individuals with liver cirrhosis, grip strength was lower in those with cirrhosis vs. the broader population of those with NAFLD.</div></div><div><h3>Conclusions</h3><div>Our study suggests that frailty is highly prevalent in individuals with NAFLD, with a significantly higher prevalence compared to those without NAFLD. Individuals with NAFLD have more than two-fold increased odds of frailty. Assessing frailty in NAFLD patients enables targeted management to improve outcomes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103187"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter to the Editor regarding “Global research trends and hotspots in gestational diabetes and long-term cardiovascular health: A bibliometric analysis.”","authors":"Hao-Han Rao , Feng Guo , Jie Tian","doi":"10.1016/j.dsx.2025.103190","DOIUrl":"10.1016/j.dsx.2025.103190","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103190"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy of microbiome-targeted interventions in obesity management- A comprehensive systematic review","authors":"Dhivya Dhanasekaran , Manojkumar Venkatesan , Sarvesh Sabarathinam","doi":"10.1016/j.dsx.2025.103208","DOIUrl":"10.1016/j.dsx.2025.103208","url":null,"abstract":"<div><h3>Background</h3><div>Obesity is a global health crisis linked to numerous chronic diseases. The gut microbiome plays a crucial role in human metabolism, and emerging evidence suggests that modulating the microbiome may offer novel therapeutic avenues for obesity management.</div></div><div><h3>Objective</h3><div>This systematic review aimed to assess the efficacy and safety of microbiome-targeted interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, in improving body composition, metabolic parameters, and inflammatory markers in overweight and obese adults.</div></div><div><h3>Methods</h3><div>A comprehensive search of PubMed, Scopus, and ScienceDirect was conducted to identify relevant studies published between 2005 and 2023. Included studies were assessed for methodological quality and risk of bias using the Cochrane Collaboration tool.</div></div><div><h3>Results</h3><div><strong>Body composition</strong>: Most studies demonstrated significant reductions in body weight, Body mass index, and body fat percentage.</div></div><div><h3>Metabolic parameters</h3><div>Improvements were observed in lipid profiles (reduced cholesterol, triglycerides) and glucose metabolism (improved insulin sensitivity).</div></div><div><h3>Inflammatory markers</h3><div>Significant reductions were observed in inflammatory markers such as Interleukins (IL-6, IL-8) and C-reactive protein.</div></div><div><h3>Microbial composition</h3><div>Interventions generally led to shifts in microbial composition, with increases in beneficial bacteria such as Bifidobacterium and Lactobacillus.</div></div><div><h3>Adverse events</h3><div>Adverse events were generally minimal and limited.</div></div><div><h3>Conclusion</h3><div>This review provides strong evidence that microbiome-targeted interventions can effectively improve body composition, metabolic parameters, and inflammatory markers in individuals with obesity. Further research is needed to optimize intervention strategies, identify specific microbial targets, and translate these findings into effective clinical applications.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103208"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Takahiro Omoto , Hyo Kyozuka , Tsuyoshi Murata , Toma Fukuda , Hirotaka Isogami , Chihiro Okoshi , Shun Yasuda , Akiko Yamaguchi , Akiko Sato , Yuka Ogata , Yuichi Nagasaka , Mitsuaki Hosoya , Seiji Yasumura , Koichi Hashimoto , Hidekazu Nishigori , Keiya Fujimori , the Japan Environment and Children's Study Group
{"title":"Relationship between preconception protein intake and gestational diabetes mellitus: The Japan Environment and Children's Study","authors":"Takahiro Omoto , Hyo Kyozuka , Tsuyoshi Murata , Toma Fukuda , Hirotaka Isogami , Chihiro Okoshi , Shun Yasuda , Akiko Yamaguchi , Akiko Sato , Yuka Ogata , Yuichi Nagasaka , Mitsuaki Hosoya , Seiji Yasumura , Koichi Hashimoto , Hidekazu Nishigori , Keiya Fujimori , the Japan Environment and Children's Study Group","doi":"10.1016/j.dsx.2025.103200","DOIUrl":"10.1016/j.dsx.2025.103200","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the relationship between preconception protein intake and the risk of gestational diabetes mellitus (GDM).</div></div><div><h3>Methods</h3><div>We analyzed data from the Japan Environment and Children's Study, focusing on 80,346 participants (mean age 31.3 ± 4.9 years; mean body mass index 21.2 ± 3.2 kg/m<sup>2</sup>) who delivered between 2011 and 2014. These participants had no history of diabetes mellitus, no previous diagnosis of GDM, and did not use steroids during pregnancy. Participants were categorized into five groups based on preconception protein energy ratio quintiles (Q1 and Q5 represent the lowest and highest intake, respectively). Continuous variables were compared using one-way analysis of variance or the Kruskal–Wallis test, and categorical variables using chi-square tests. Primary outcomes were GDM, early-diagnosed GDM (Ed-GDM, diagnosed at <24 weeks), and late-diagnosed GDM (Ld-GDM, diagnosed at >24 weeks). Adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) were calculated using logistic regression analysis with the middle quintile (Q3) as the reference.</div></div><div><h3>Results</h3><div>Multiple logistic regression analysis revealed that using the Q3 group as the reference, the Q5 group had a higher risk of Ed-GDM (aOR 1.48, 95 % CI 1.06–2.07), whereas the Q1 group had a lower risk of Ed-GDM (aOR 0.69, 95 % CI 0.48–0.996). However, no significant differences were observed in the risk of GDM and Ld-GDM.</div></div><div><h3>Conclusions</h3><div>Higher preconception protein intake was associated with increased Ed-GDM risk. Further research is needed to refine dietary recommendations for preconception protein intake.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103200"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143228576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yanxi Jia , Qing Hu , Hua Liao , Hongyan Liu , Zhaomin Zeng , Haiyan Yu
{"title":"Response to the Letter to the Editor regarding “Global research trends and hotspots in gestational diabetes and long-term cardiovascular health: A bibliometric analysis.”","authors":"Yanxi Jia , Qing Hu , Hua Liao , Hongyan Liu , Zhaomin Zeng , Haiyan Yu","doi":"10.1016/j.dsx.2025.103191","DOIUrl":"10.1016/j.dsx.2025.103191","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103191"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Choon Ming Ng, Wing Loong Cheong, Chun Wie Chong, Siew Li Teoh, Wuan Shuen Yap, Shaun Wen Huey Lee
{"title":"Digital technologies for prediabetes: A systematic review and meta-analysis","authors":"Choon Ming Ng, Wing Loong Cheong, Chun Wie Chong, Siew Li Teoh, Wuan Shuen Yap, Shaun Wen Huey Lee","doi":"10.1016/j.dsx.2025.103206","DOIUrl":"10.1016/j.dsx.2025.103206","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103206"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143403222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Huiwon Kang , Un Jae Lee , Bum Yong Park , Minju Kim , Mihi Yang
{"title":"Effects of deep ocean-derived magnesium-enhanced water on metabolic diseases with microbiome changes","authors":"Huiwon Kang , Un Jae Lee , Bum Yong Park , Minju Kim , Mihi Yang","doi":"10.1016/j.dsx.2025.103203","DOIUrl":"10.1016/j.dsx.2025.103203","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the effects of magnesium (Mg) from deep ocean sources, we conducted a randomized clinical trial involving adults with hypertension, diabetes, or hyperlipidemia.</div></div><div><h3>Methods</h3><div>Subjects consumed either Mg-enriched water (MEW) or a placebo (80 or 6 mg of Mg per 2 L/day, respectively) for 4 weeks. We examined the detoxifying effects of MEW on environmental toxicants, including polycyclic aromatic hydrocarbons (PAHs) and oxidative stress, and its impact on gut microbiome composition (N = 30; 49.26 ± 9.55 yrs).</div></div><div><h3>Results</h3><div>Most subjects consumed less Mg than the RDA, enabling their participation in the trial. Despite limitations in serum Mg measurement to assess Mg intake, MEW intake led to improvements in body mass index (BMI), insulin levels, triglycerides, glucose-BMI, and fatigue. Regardless of Mg content, water consumption reduced urinary levels of 1-hydroxypyrene, a major PAH metabolite, and malondialdehyde, an oxidative stress biomarker. Moreover, the MEW group exhibited greater diversity in gut microbiome composition than the placebo group. Notably, MEW kept the abundance of <em>Clostridium</em>, <em>Dorea</em>, or <em>Desulfovibrio</em>, indicating a balanced Mg intake.</div></div><div><h3>Conclusion</h3><div>MEW (80 mg of Mg/day) appears safe for RDA and effective for preventing CVD or T2DM, as evidenced by gut microbiome and biomarker outcomes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103203"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mallika Prem Senthil , Eilish Devlin , Abolfazl Hassani, Eugene Lee, Royston Yi Sheng An, Steven Oh, Joshua Barclay, Muhammad Husnain, Jose J. Estevez, Ranjay Chakraborty
{"title":"The role of melatonin and circadian rhythms in the pathogenesis of diabetic retinopathy: A systematic review","authors":"Mallika Prem Senthil , Eilish Devlin , Abolfazl Hassani, Eugene Lee, Royston Yi Sheng An, Steven Oh, Joshua Barclay, Muhammad Husnain, Jose J. Estevez, Ranjay Chakraborty","doi":"10.1016/j.dsx.2025.103202","DOIUrl":"10.1016/j.dsx.2025.103202","url":null,"abstract":"<div><h3>Aims</h3><div>This review investigates literature on systemic melatonin levels and circadian timing in diabetic retinopathy (DR), examining their associations with DR.</div></div><div><h3>Methods</h3><div>Our search was conducted in March 14, 2024, and included the databases Medline, Web of Science, Scopus, ProQuest Health, Latin American and Caribbean Health Sciences Literature (LILACS), Cochrane, International Standard Randomised Controlled Trial Number (ISRCTN) registry, and International Clinical Trials Registry Platform (ICTRP).</div></div><div><h3>Results</h3><div>Our review analysed twelve articles measuring melatonin concentration in saliva, blood serum, urine, or aqueous humour. Studies measuring melatonin levels in saliva found no significant differences in the average nocturnal or daytime melatonin levels between type 2 diabetes (T2D) patients with and without DR. The studies comparing serum melatonin levels in patients with different stages of DR and controls showed inconsistent results. Only two studies measured the endogenous onset of melatonin secretion, known as dim light melatonin onset (DLMO), a highly accurate biomarker for circadian regulation. These studies showed that only 33% and 57% of patients with DR had detectable DLMO in saliva and serum, respectively. All studies evaluating overnight melatonin production using urinary aMT6s (urinary 6-sulfaoxymelatonin) levels found that DR was associated with lower nocturnal melatonin production.</div></div><div><h3>Conclusions</h3><div>Our review results showed evidence of reduced nocturnal melatoin production in DR with no significant changes in melatonin circadian timing.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103202"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Agreement and disagreement between diagnostic criteria for gestational diabetes and implications for clinical practice: A retrospective observational study","authors":"Alpesh Goyal , Rahul Gupta , Avantika Gupta , Astha Yadav , Ashish Jadhav , Rekha Singh","doi":"10.1016/j.dsx.2025.103207","DOIUrl":"10.1016/j.dsx.2025.103207","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate agreement/disagreement between eleven gestational diabetes (GDM) diagnostic criteria, including five used in current clinical practice globally.</div></div><div><h3>Methods</h3><div>Records of 353 pregnant women with oral glucose tolerance test performed after 20 weeks of gestation were retrospectively reviewed. The diagnosis of GDM was compared using the IADPSG, DIPSI, WHO 1999, CDA 2003 and 2013, NICE 2015, JSOG 1984, ADIPS 1998, ADA 2004, NZSSD 2004 and EASD 1996 criteria. The agreement between criteria was expressed as Cohen's kappa coefficient (k; 0.4–0.6, moderate; 0.6–0.8, good; 0.8–1.0, very good) and disagreement as percentage (d). IADPSG criteria were used as a reference for comparison.</div></div><div><h3>Results</h3><div>The prevalence of GDM varied from 7.4 % (95 % CI, 4.9–10.4 %) by CDA 2003 criteria to 23.8 % (95 % CI, 19.5–28.4 %) by IADPSG criteria. Of the 55 pair-wise criteria comparisons, 29 (52.7 %) showed moderate, 16 (29.1 %) good, and 10 (18.2 %) very good agreement. Among the currently used criteria, the CDA 2013 (k = 0.811; d = 6.2 %) agreed the most, the DIPSI/WHO 1999 (k = 0.456) agreed the least, and the NICE 2015 (k = 0.580) criteria showed an intermediate agreement with the IADPSG criteria.</div></div><div><h3>Conclusions</h3><div>There is a marked variation in the prevalence of GDM, with a significant degree of disagreement between different diagnostic criteria. The study findings should be interpreted in the context of its retrospective nature and non-consecutive recruitment, which introduce a potential for selection bias.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103207"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rakesh.M. Parikh , Banshi Saboo , Anoop Misra , Abdul Basit , S.R. Aravind , Bishwajit Bhowmik , Peter Schwarz , Ketan Dhatariya , Kamlesh Khunti , Shashank Joshi , Sunil Gupta , Amit Gupta , Manoj Chawla , Sanjeev Phatak , Sanjay Kalra , Azad Khan , Viswanathan Mohan
{"title":"Ahmedabad declaration: A framework to combat growing epidemic of young-onset type 2 diabetes in Asia","authors":"Rakesh.M. Parikh , Banshi Saboo , Anoop Misra , Abdul Basit , S.R. Aravind , Bishwajit Bhowmik , Peter Schwarz , Ketan Dhatariya , Kamlesh Khunti , Shashank Joshi , Sunil Gupta , Amit Gupta , Manoj Chawla , Sanjeev Phatak , Sanjay Kalra , Azad Khan , Viswanathan Mohan","doi":"10.1016/j.dsx.2025.103205","DOIUrl":"10.1016/j.dsx.2025.103205","url":null,"abstract":"<div><h3>Aim</h3><div>Rising prevalence of Type 2 Diabetes (T2D) among young Asians has emerged as a public health crisis that threatens the long-term health, economic stability, and productivity of nations across Asia (1). Early-onset T2D poses unique challenges, including higher rates of undiagnosed cases, more aggressive disease progression, an increased risk of chronic complications and higher mortality (2). Hyperglycemia during the reproductive age especially among the female population can potentially have transgenerational impact through epigenetic changes.</div></div><div><h3>Methods</h3><div>A comprehensive search was conducted on PubMed with a combination of relevant keywords. A preliminary draft prepared after review of literature was electronically circulated among a panel of 64 experts from various parts of the region and representatives of the participating organizations - Diabetes India (<span><span>www.diabetesindia.org.in</span><svg><path></path></svg></span>) and the Diabetes Asia Study Group (DASG, <span><span>www.da-sg.org</span><svg><path></path></svg></span>).</div></div><div><h3>Results</h3><div>This Ahmedabad Declaration outlines the scale of the problem, its root causes, and a comprehensive action plan for Asian populations. The objectives of this declaration include raising awareness, addressing systemic barriers, and advocating for evidence-based policies and interventions, limited to people with T2D. Through collaborative efforts, we aim to mitigate the growing burden of diabetes in young Asians and secure a healthier future.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103205"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}